Frontotemporal Cognitive Disorder
Resources for Patients and Caregivers
Frontotemporal disorders (FTD), sometimes called frontotemporal dementia, are the result of damage to neurons in the frontal and temporal lobes of the brain. Many possible symptoms can result, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking.
Cluster Number:
Wiki Number: 19-Frontotemporal Cognitive Disorder
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area: frontal lobe
Symptoms: difficulties with cognitive (movement and speech), emotional or behavioral activities
Progression:
Causes: brain injuries, frontotemporal-dementia or Alzheimer’s diseases
Medications:
Therapies: speech therapy
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Editorial: Cognitive and Behavioral Features in ALS: Beyond Motor Impairment in ALS-FTD Spectrum Disordersby Enrica Bersano on July 1, 2022
No abstract
- Development of informant-reported or self-reported MCI-J questionnaireby Takashi Asada on July 1, 2022
CONCLUSIONS: This questionnaire could promote earlier presentation to clinical settings for treatment. The high sensitivity indicates the utility of this instrument, but it is not meant as a definitive diagnostic tool and should be followed with a professional assessment.
- Frontotemporal Dementiaby Katherine Marshall on July 1, 2022
No abstract
- Multi-omics profiling identifies a deregulated FUS-MAP1B axis in ALS/FTD-associated UBQLN2 mutantsby Laura Strohm on July 1, 2022
Ubiquilin-2 (UBQLN2) is a ubiquitin-binding protein that shuttles ubiquitinated proteins to proteasomal and autophagic degradation. UBQLN2 mutations are genetically linked to the neurodegenerative disorders amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). However, it remains elusive how UBQLN2 mutations cause ALS/FTD. Here, we systematically examined proteomic and transcriptomic changes in patient-derived lymphoblasts and CRISPR/Cas9-engineered HeLa cells carrying ALS/FTD...